Current perspectives on FTY720

Expert Opinion on Investigational Drugs

Volumn 16, Issue 4, 2007, Pages 505-518

  Martini, Sebastian ^a   Peters, Harm ^a   Böhler, Torsten ^b   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CHU RANGUEIL   (France)

Author keywords

Fingolimod; FTY; FTY720; Multiple sclerosis; Renal transplantation; Sphingosine 1 phosphate

Indexed keywords

ATROPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CALCINEURIN INHIBITOR; CYCLOSPORIN A; FINGOLIMOD; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STEROID; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

AIRWAY OBSTRUCTION; ALLERGIC ENCEPHALITIS; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BACKACHE; BLOOD ANALYSIS; BONE MARROW TOXICITY; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONVULSION; COUGHING; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; ENDOMETRIOSIS; EXTRASYSTOLE; FORCED EXPIRATORY VOLUME; GRAFT SURVIVAL; HEART PALPITATION; HEART RATE; HUMAN; HYALINE DEGENERATION; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; LUNG FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MULTIPLE DRUG DOSE; MULTIPLE SCLEROSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHARMACODYNAMICS; REGULATORY MECHANISM; REPERFUSION INJURY; RESPIRATORY TRACT DISEASE; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SPIROMETRY; SYSTEMIC DISEASE; THORAX PAIN; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 34147117343     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.4.505     Document Type: Review

References (92)

1. PUGLIAITI M, ROSATI G, CARTON H et al.: The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. (2006) 13(7):700-722.
2. NISHIKAWA K, TERASAKI PI: Annual trends and triple therapy - 1991 - 2000. Clin. Transpl. (2001):247-269.
3. JARDINE AG, FELLSTROM B, LOGAN JO et al.: Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study. Am. J. Kidney Dis. (2005) 46(3):529-536.
4. LENTINE KL, BRENNAN DC, SCHNITZLER MA: Incidence and predictors of myocardial infarction after kidney transplantation. J. Am. Soc. Nephrol. (2005) 16(2):496-506.
5. BUDDE K, SCHMOUDER RL, BRUNKHORST R et al.: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. (2002) 13(4):1073-1083.
6. SUZUKI S, ENOSAWA S, KAKEFUDA T et al.: A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation (1996) 61(2):200-205.
7. GOODIN DS, FROHMAN EM, GARMANY GP Jr et al.: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 58(2):169-178.
8. 1 receptor agonists. Bioorg. Med. Chem. Lett. (2005) 15(15):3568-3572.
9. KUNZENDORF U, ZIEGLER E, KABELITZ D: FTY720 - the first compound of a new promising class of immunosuppressive drugs. Nephrol. Dial. Transplant. (2004) 19(7):1677-1681.
10. PINSCHEWER DD, OCHSENBEIN AF, ODERMATT B et al.: FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. (2000) 164(11):5761-5770.
11. BRINKMANN V, DAVIS MD, HEISE CE et al.: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. (2002) 277(24):21453-21457.
12. ZHANG H, DESAI NN, OLIVERA A et al.: Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J. Cell Biol. (1991) 114(1):155-167.
13. VOGLER R, SAUER B, KIM DS, SCHAFER-KORTING M, KLEUSER B: Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. J. Invest. Dermatol. (2003) 120(4):693-700.
14. WANG F, NOHARA K, OLIVERA A, THOMPSON EW, SPIEGEL S: Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate. Exp. Cell Res. (1999) 247(1):17-28.
15. IM DS: Linking Chinese medicine and G-protein-coupled receptors. Trends Pharmacol. Sci. (2003) 24(1):2-4.
16. CHIBA K, YANAGAWA Y, MASUBUCHI Y et al.: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. (1998) 160(10):5037-5044.
17. YAGI H, KAMBA R, CHIBA K et al.: Immunosuppressant FTY720 inhibits thymocyte emigration. Eur. J. Immunol. (2000) 30(5):1435-1444.
18. BRINKMANN V, WILT C, KRISTOFIC C et al.: FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant. Proc. (2001) 33(7-8):3078-3080.
19. BOHLER T, WAISER J, SCHUTZ M et al.: FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism. Transpl. Int. (2000) 13(Suppl. 1):S311-S313.
20. AZUMA H, TAKAHARA S, ICHIMARU N et al.: Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. (2002) 62(5):1410-1419.
21. LAMONTAGNE K, LITTLEWOOD-EVANS A, SCHNELL C et al.: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. (2006) 66(1):221-231.
22. LEE TK, MAN K, HO JW et al.: FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin. Cancer Res. (2005) 11(23):8458-8466.
23. SCHMID G, GUBA M, PAPYAN A et al.: FTY720 inhibits tumor growth and angiogenesis. Transplant. Proc. (2005) 37(1):110-111.
24. ZHOU C, LING MT, KIN-WAH LEE T et al.: FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett. (2006) 233(1):36-47.
25. BILLICH A, BORNANCIN F, DEVAY P et al.: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. (2003) 278(48):47408-47415.
26. PAUGH SW, PAYNE SG, BARBOUR SE, MILSTIEN S, SPIEGEL S: The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. (2003) 554(1-2):189-193.
27. MATLOUBIAN M, LO CG, CINAMON G et al.: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (2004) 427(6972):355-360.
28. GRALER MH, GOETZL EJ: The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. (2004) 18(3):551-553.
29. BRINKMANN V, CYSTER JG, HLA T: FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. (2004) 4(7):1019-1025.
30. BOHLER T, BUDDE K, NEUMAYER HH, WAISER J: Novel mediators of FTY720 in human lymphocytes. Transplantation (2005) 79(4):492-495.
31. LEE MJ, THANGADA S, CLAFFEY KP et al.: Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell (1999) 99(3):301-312.
32. 3. Circ. Res. (2005) 96(8):913-920.
33. BUDDE K, L SCHMOUDER R, NASHAN B et al.: Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am. J. Transplant. (2003) 3(7):846-854.
34. KAHAN BD, KARLIX JL, FERGUSON RM et al.: Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, Phase I study. Transplantation (2003) 76(7):1079-1084.
35. YANAGAWA Y, MASUBUCHI Y, CHIBA K: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology (1998) 95(4):591-594.
36. SKERJANEC A, TEDESCO H, NEUMAYER HH et al.: FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J. Clin. Pharmacol. (2005) 45(11):1268-1278.
37. TEDESCO-SILVA H, MOURAD G, KAHAN BD et al.: FTY720, a novel immunomodulator: efficacy and safety results from the first Phase IIA study in de novo renal transplantation. Transplantation (2004) 77(12):1826-1833.
38. ROSEN H, GOETZL EJ: Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. (2005) 5(7):560-570.
39. BRINKMANN V, PINSCHEWER D, CHIBA K, FENG L: FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol. Sci. (2000) 21(2):49-52.
40. HABICHT A, CLARKSON MR, YANG J et al.: Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J. Immunol. (2006) 176(1):36-42.
41. DRAGUN D, BOHLER T, NIEMINEN-KELHA M et al.: FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. Kidney Int. (2004) 65(3):1076-1083.
42. OJO AO, WOLFE RA, HELD PJ, PORT FK, SCHMOUDER RL: Delayed graft function: risk factors and implications for renal allograft survival. Transplantation (1997) 63(7):968-974.
43. ANSELMO D, AMERSI FF, SHEN XD et al.: FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury. Transplant. Proc. (2002) 34(5):1467-1468.
44. ANSELMO DM, AMERSI FF, SHEN XD et al.: FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am. J. Transplant. (2002) 2(9):843-849.
45. MAN K, NG KT, LEE TK et al.: FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am. J. Transplant. (2005) 5(1):40-49.
46. YAN SF, FUJITA T, LU J et al.: Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat. Med. (2000) 6(12):1355-1361.
47. FUJISHIRO J, KUDOU S, IWAI S et al.: Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation (2006) 82(6):804-812.
48. FUJISHIRO J, SUZUKI C, KUDOU S et al.: Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats. J. Heart Lung Transplant. (2006) 25(7):825-833.
49. SUZUKI C, TAKAHASHI M, MORIMOTO H et al.: Efficacy of mycophenolic acid combined with KRP-203, a novel immunomodulator, in a rat heart transplantation model. J. Heart Lung Transplant. (2006) 25(3):302-309.
50. 1-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int. (2006) 69(9):1601-1608.
51. AKI FT, KAHAN BD: FTY720: a new kid on the block for transplant immunosuppression. Expert Opin. Biol. Ther. (2003) 3(4):665-681.
52. BRINKMANN V, LYNCH KR: FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. (2002) 14(5):569-575.
53. lpr/lpr mice treated with FTY720. Clin. Exp. Immunol. (1997) 107(1):103-111.
54. lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J. Rheumatol. (2002) 29(4):707-716.
55. JEVNIKAR AM, GRUSBY MJ, GLIMCHER LH: Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J. Exp. Med. (1994) 179(4):1137-1143.
56. LUSTER AD, ALON R, VON ANDRIAN UH: Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. (2005) 6(12):1182-1190.
57. KARNI A, ABRAHAM M, MONSONEGO A et al.: Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. (2006) 177(6):4196-4202.
58. KATAOKA H, SUGAHARA K, SHIMANO K et al.: FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol. Immunol. (2005) 2(6):439-448.
59. FUJINO M, FUNESHIMA N, KITAZAWA Y et al.: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. (2003) 305(1):70-77.
60. WEBB M, THAM CS, LIN FF et al.: Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. (2004) 153(1-2):108-121.
61. RE F, BELYANSKAYA SL, RIESE RJ et al.: Granulocyte-macrophage colony-stimulating factor induces an expression program in neonatal microglia that primes them for antigen presentation. J. Immunol. (2002) 169(5):2264-2273.
62. 5 inhibits oligodendrocyte progenitor migration. FASEB J. (2007) (In Press).
63. PETERS H, MARTINI S, WANG Y et al.: Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy I glomerulosclerosis. Kidney Int. (2004) 66(4):1434-1443.
64. YOUNG BA, BURDMANN EA, JOHNSON RJ et al.: Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int. (1995) 48(2):431-438.
65. 1 in experimental chronic cyclosporine nephropathy. Kidney Int. (1996) 49(4):1141-1151.
66. YANG CW, AHN HJ, KIM WY et al.: Influence of the rennin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney. Kidney Int. (2001) 60(3):847-857.
67. KIM JY, LIM SW, LI C et al.: Effect of FTY720 on chronic cyclosporine nephropathy in rats. Transplantation (2005) 80(9):1323-1330.
68. XIN C, REN S, EBERHARDT W, PFEILSCHIFTER J, HUWILER A: The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br. J. Pharmacol. (2006) 147(2):164-174.
69. MANDALA S, HAJDU R, BERGSTROM J et al.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 296(5566):346-349.
70. HOJO M, MORIMOTO T, MALUCCIO M et al.: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 397(6719):530-534.
71. TANAKA T, TAKAHARA S, HATORI M et al.: A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett. (2002) 181(2):165-171.
72. AZUMA H, HORIE S, MUTO S et al.: Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity.. Anti-Cancer Res. (2003) 23(4):3183-3193.
73. NAGAHARA Y, IKEKITA M, SHINOMIYA T: T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br. J. Pharmacol. (2002) 137(7):953-962.
74. LIU Y, WADA R, YAMASHITA T et al.: Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. (2000) 106(8):951-961.
75. SCHMID G, GUBA M, ISCHENKO I et al.: The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J. Cell Biochem. (2007) (In Press).
76. CHUA CW, LEE DT, LING MT et al.: FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int. J. Cancer (2005) 117(6):1039-1048.
77. EASTON JB, HOUGHTON PJ: mTOR and cancer therapy. Oncogene (2006) 25(48):6436-6446.
78. ASSMANN G, GOTTO AM Jr: HDL cholesterol and protective factors in atherosclerosis. Circulation (2004) 109(23 Suppl. 1):III8-III14.
79. 3. J. Clin. Invest. (2004) 113(4):569-581.
80. NOFER JR, ASSMANN G: Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. (2005) 15(7):265-271.
81. KEUL P, TOLLE M, LUCKE S et al.: The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2007) 27(3):607-613.
82. NOFER JR, BOT M, BRODDE M et al.: FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2007) 115(4):501-508.
83. ZHOU X, PAULSSON G, STEMME S, HANSSON GK: Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. (1998) 101(8):1717-1725.
84. 1 G protein-coupled receptor. J. Immunol. (2003) 171(7):3500-3507.
85. JIN Y, KNUDSEN E, WANG L et al.: Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood (2003) 101(12):4909-4915.
86. 3 receptor. Arterioscler. Thromb. Vasc. Biol. (2007) 27(2):275-282.
87. ROSS R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. (1999) 340(2):115-126.
88. MULGAONKAR S, TEDESCO H, OPPENHEIMER F et al.: FTY720/ cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am. J. Transplant. (2006) 6(8):1848-1857.
89. SALVADORI M, BUDDE K, CHARPENTIER B et al.: FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant. (2006) 6(12):2912-2921.
90. TEDESCO-SILVA H, PESCOVITZ MD, CIBRIK D et al.: Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation (2006) 82(12):1689-1697.
91. GALETTA SL, MARKOWITZ C: US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs (2005) 19(3):239-252.
92. KAPPOS L, ANTEL J, COMI G et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 355(11):1124-1140.